Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200085 | 0.77 | KDM1A (0.39) | NPC1RAB9AALDH1A1LMNAHPGD | |
| Methane SCHEMBL28793204 | 0.77 | NPC1 (0.40) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL28096454 | 0.72 | NPC1 (0.47) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL14491867 | 0.72 | NPC1 (0.43) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL7032038 | 0.70 | NPC1 (0.41) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL28972364 | 0.70 | HDAC1 (0.39) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL29661291 | 0.70 | NPC1 (0.45) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL21523846 | 0.67 | SIGMAR1 (0.41) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL21242823 | 0.66 | NPC1 (0.35) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL4331066 | 0.65 | ALDH1A1 (0.42) | NPC1RAB9AALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241524-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241524-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | OPRK1, OPRL1, ACHE | NPC1 1507/4885RAB9A 3442/4885ALDH1A1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.